Compare · DXCM vs TNDM
DXCM vs TNDM
Side-by-side comparison of DexCom Inc. (DXCM) and Tandem Diabetes Care Inc. (TNDM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and TNDM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $23.67B, about 17.8x TNDM ($1.33B).
- DXCM has been more active in the news (8 items in the past 4 weeks vs 5 for TNDM).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- Tandem Diabetes Care Inc.
- Price
- -
- -
- Market cap
- $23.67B
- $1.33B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2013
- News (4w)
- 8
- 5
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Tandem Diabetes Care Inc.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Latest DXCM
- SEC Form 10-Q filed by DexCom Inc.
- DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dexcom Reports First Quarter 2026 Financial Results
- Why Medtech Giants Are Quietly Paying Up for AI Diagnostics
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
Latest TNDM
- Tandem Diabetes Care Announces Upcoming Conference Presentations
- Tandem Diabetes Care's Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes
- SEC Form 4 filed by Kyrillos Jean-Claude
- SEC Form DEF 14A filed by Tandem Diabetes Care Inc.
- SEC Form DEFA14A filed by Tandem Diabetes Care Inc.
- Tandem Diabetes Care to Announce First Quarter 2026 Financial Results on May 7, 2026
- SEC Form PRE 14A filed by Tandem Diabetes Care Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Tandem Diabetes Care Inc.
- Tandem Diabetes Care upgraded by Truist with a new price target
- SEC Form 4 filed by Novara Mark David